Lower inflammation is related to greater energy levels in adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor
Elexacaftor/tezacaftor/ivacaftor can be effective for people with cystic fibrosis with the 3849 gene variant
Two-year follow-up results from an ongoing study on the safety and effectiveness of elexacaftor/tezacaftor/ivacaftor when used in real-world settings by people with cystic fibrosis
Testicular pain following initiation of elexacaftor/tezacaftor/ivacaftor in males with cystic fibrosis
New drug for cystic fibrosis does not significantly interfere with another drug that prevents organ rejection
